Fig 4. The performance of PDRWH and other four methods for identifying the known tumor-specific driver genes.

(A) The percentage of patients whose predicted personalized drivers are significantly enriched in the known tumor-specific driver gene list. (B) Comparison of the number of predicted tumor-specific driver genes by various methods and the recall ratio. (C) Overlap among the tumor-specific cancer drivers predicted by different methods for BRCA, KIRC, and LIHC.